These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8123178)

  • 1. Treatment of leukemia in relapse after bone marrow transplantation.
    de Witte T; Schattenberg T
    N Engl J Med; 1994 Mar; 330(9):645; author reply 645-6. PubMed ID: 8123178
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
    Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Present status of donor leukocyte transfusion for leukemia. Relapse after allogeneic bone marrow transplantation in Japan].
    Morishima Y; Kodera Y
    Rinsho Ketsueki; 1997 Jun; 38(6):476-8. PubMed ID: 9248321
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
    Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S
    Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgrastim for the treatment of leukemia relapse after bone marrow transplantation.
    Carral A; Sanz GF; Sanz MA
    Bone Marrow Transplant; 1996 Oct; 18(4):817-9. PubMed ID: 8899204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation].
    Kanamori H; Sasaki S; Ueda S; Yamazaki E; Tamura T; Harano H; Matsuzaki M; Ogawa K; Mohri H; Okubo T
    Rinsho Ketsueki; 1997 Aug; 38(8):643-6. PubMed ID: 9311269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.
    Lee KH; Lee JH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Seo EJ; Park CJ; Chi HS; Lee JS
    Bone Marrow Transplant; 2003 Oct; 32(8):835-42. PubMed ID: 14520431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.
    Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE
    J Clin Oncol; 2004 Dec; 22(24):4872-80. PubMed ID: 15520055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation.
    Lee KH; Lee JH; Kim S; Lee JS; Kim SH; Kim WK
    Bone Marrow Transplant; 2000 Jul; 26(2):147-52. PubMed ID: 10918424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group.
    Sao H; Kato C; Kitaori K; Adachi T; Yano K; Kobayashi M; Kojima H; Tanimoto M; Hirabayashi N; Minami S; Yamada H; Morishita GY; Morishima Y; Kodera Y
    Int J Hematol; 2000 Aug; 72(2):237-42. PubMed ID: 11039675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.